Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23342369 | 0.84 | HTR2A (0.37) | HSD17B10 | |
| SCHEMBL23341665 | 0.80 | PDK2 (0.32) | — | |
| SCHEMBL25895338 | 0.76 | NPC1 (0.41) | KDM4EMAPK1HSD17B10ALDH1A1 | |
| SCHEMBL25895328 | 0.68 | HTR3E (0.35) | MAPK1ALDH1A1 | |
| SCHEMBL8256542 | 0.67 | KDM4E (0.41) | KDM4EMAPK1NPSR1HSD17B10ALDH1A1 | |
| SCHEMBL26137718 | 0.67 | TRPA1 (0.47) | KDM4EALDH1A1 | |
| SCHEMBL25912981 | 0.67 | IDO1 (0.38) | HSD17B10 | |
| SCHEMBL791955 | 0.66 | TAAR1 (0.52) | KDM4EMAPK1NPSR1HSD17B10ALDH1A1 | |
| SCHEMBL25895358 | 0.65 | ACHE (0.41) | KDM4EMAPK1NPSR1ALDH1A1 | |
| SCHEMBL23342611 | 0.65 | CYP1B1 (0.45) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739074-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739074-B2 | Ras inhibitors | KRAS, NRAS, HRAS | KDM4E 3344/4885MAPK1 162/4885NPSR1 4065/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | KDM4E 2157/4885MAPK1 769/4885NPSR1 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.